A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Administration of EC-18 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2016
At a glance
- Drugs EC 18 (Primary)
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Enzychem Lifesciences Corporation
- 08 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Jul 2015 New trial record